Genelux (NASDAQ:GNLX – Get Free Report) and BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Genelux and BioMarin Pharmaceutical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 3 | 2.80 |
Genelux presently has a consensus target price of $20.00, indicating a potential upside of 974.11%. BioMarin Pharmaceutical has a consensus target price of $87.91, indicating a potential upside of 54.55%. Given Genelux’s higher probable upside, analysts clearly believe Genelux is more favorable than BioMarin Pharmaceutical.
Risk & Volatility
Genelux has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
Insider and Institutional Ownership
37.3% of Genelux shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Genelux and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -205.85% | -138.79% |
| BioMarin Pharmaceutical | -0.52% | 5.58% | 3.51% |
Earnings & Valuation
This table compares Genelux and BioMarin Pharmaceutical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genelux | $10,000.00 | 8,423.69 | -$32.15 million | ($0.86) | -2.17 |
| BioMarin Pharmaceutical | $3.22 billion | 3.42 | $348.90 million | ($0.10) | -568.85 |
BioMarin Pharmaceutical has higher revenue and earnings than Genelux. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Genelux on 9 of the 15 factors compared between the two stocks.
About Genelux
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
